Medline Inc.
MDLN Healthcare Medical Instruments & Supplies
Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024.
- Revenue
- +14.1%
- Free cash flow
- +916.1%
- Total debt
- −23.7%
Quarter to September 2026, against a year earlier
Follow MDLN
Alert me
Medline Inc. (MDLN) EV/FCF
As of 5 November 2026, Medline Inc. (MDLN) trades at a EV/FCF of 14.5×. Over the past ten years it has ranged from 4.7× (December 2025) to 21.8× (April 2026); the current reading is higher than 39% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 13.2× | 183.12% |
| FY2024 | 4.7× | 0.00% |
| FY2023 | 4.7× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 13.0× | (31.45%) |
| Jun 2026 | 19.0× | (7.40%) |
| Mar 2026 | 20.5× | 55.22% |
| Dec 2025 | 13.2× | 183.12% |
| 2 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SOLV Solventum Corporation compare | 0.0× |
| MDLN Medline Inc. | 14.5× |
| BAX Baxter International Inc. compare | 17.5× |
| RMD ResMed Inc. compare | 21.0× |
| COO The Cooper Companies, Inc. compare | 21.6× |
| BDX Becton, Dickinson and Company compare | 22.2× |
| ALC Alcon compare | 25.4× |
| ISRG Intuitive Surgical, Inc. compare | 43.5× |
| WST West Pharmaceutical Services, Inc. compare | 61.0× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on MDLN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Book value per share
- The full statement